{"analyses":[{"ciLowerLimit":"-0.046","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.045","groupDescription":"Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.5052","paramType":"Difference in LS Mean","paramValue":"0","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.050","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.042","groupDescription":"Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.5599","paramType":"Difference in LS Mean","paramValue":"-0.004","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.030","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.064","groupDescription":"Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.2770","paramType":"Difference in LS Mean","paramValue":"0.017","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.071","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.070","groupDescription":"95th Percentile of Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.5047","paramType":"Difference in LS Mean","paramValue":"0","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.097","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.045","groupDescription":"95th Percentile of Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG002"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.7316","paramType":"Difference in LS Mean","paramValue":"-0.026","statisticalMethod":"MMRM analysis; 1-sided"},{"ciLowerLimit":"-0.063","ciNumSides":"TWO_SIDED","ciPctValue":"90","ciUpperLimit":"0.082","groupDescription":"95th Percentile of Gait Speed: MMRM model included participant as a random term, and baseline, time (as a factor), baseline-by-time interaction, treatment and treatment-by-time interaction, type of therapy \\[platinum or not at randomization +/- 28 days\\], and type of cancer as fixed terms, with an unstructured covariance matrix and Kenwood-Roger degrees of freedom.","groupIds":["OG000","OG003"],"nonInferiorityType":"SUPERIORITY","pValue":"=0.4145","paramType":"Difference in LS Mean","paramValue":"0.01","statisticalMethod":"MMRM analysis; 1-sided"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.042","upperLimit":"0.026","value":"-0.008"},{"groupId":"OG001","lowerLimit":"-0.040","upperLimit":"0.023","value":"-0.009"},{"groupId":"OG002","lowerLimit":"-0.044","upperLimit":"0.019","value":"-0.012"},{"groupId":"OG003","lowerLimit":"-0.024","upperLimit":"0.042","value":"0.009"}]}],"title":"Gait Speed"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.041","upperLimit":"0.064","value":"0.011"},{"groupId":"OG001","lowerLimit":"-0.037","upperLimit":"0.059","value":"0.011"},{"groupId":"OG002","lowerLimit":"-0.063","upperLimit":"0.033","value":"-0.015"},{"groupId":"OG003","lowerLimit":"-0.030","upperLimit":"0.072","value":"0.021"}]}],"title":"95th percentile of gait speed"}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"14"}],"units":"Participants"}],"description":"Gait was monitored using accelerometry (wearable digital sensors). Analysis was performed using MMRM model. Gait included: gait speed and 95th percentile of gait speed. Baseline was defined as the mean taken over the 8 days of wear during screening. Mean taken over the 8 days of wear before Week 12 was considered. Analysis was performed using MMRM model.","dispersionType":"90% Confidence Interval","groups":[{"description":"Part A: Participants were randomized to receive placebo matching to Ponsegromab SC Q4W up to 12 weeks (total of 3 doses).","id":"OG000","title":"Part A: Placebo"},{"description":"Part A: Participants were randomized to receive Ponsegromab 100 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG001","title":"Part A: Ponsegromab 100 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 200 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG002","title":"Part A: Ponsegromab 200 mg"},{"description":"Part A: Participants were randomized to receive Ponsegromab 400 mg SC Q4W up to 12 weeks (total of 3 doses).","id":"OG003","title":"Part A: Ponsegromab 400 mg"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Censored analysis set:all evaluable participants.For participants who discontinued study intervention/received prohibited procedure/ prohibited medication,all observations post-discontinuation/post-procedure,were censored and treated as missing data.For participants who missed dose/received incomplete dose,all observations post-missed/incomplete dose were censored and treated as missing data.''Overall Number of Participants Analyzed'' =participants evaluable for this outcome measure at Week 12.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 12","title":"Part A: Change From Baseline in Gait at Week 12","type":"SECONDARY","unitOfMeasure":"Meter per second (m/s)"}